Have any questions? 706-721-6582 or cts@augusta.edu
- A multi-center, randomized, controlled trial of Brexpiprazole for the treatment of co-occurring schizophrenia and substance use disorder.
Clinical Trial
A multi-center, randomized, controlled trial of Brexpiprazole for the treatment of co-occurring schizophrenia and substance use disorder.
The proposed study is a 3-site, 12-week, feasibility, proof of concept investigation of patients who have co-occurring diagnoses of schizophrenia and current substance use disorder (alcohol, cocaine, heroin, or cannabis). The primary objectives of this study is to examine the effect of brexpiprazole treatment on the number of days of substance use in the past week as measured by the Timeline Follow Back assessment and to examine the effect of brexpiprazole treatment on substance craving using 100-mm visual analogue scale.
Eligibility Criteria
- Inclusion Criteria: 1. Age 18 - 65 years old 2. Meets DSM-5 criteria for diagnoses of schizophrenia disorder and substance use disorder based on the Mini International Neuropsychiatric Interview. 3. Uses sustance on at least 4 of the past 30 days prior to randomization with at least one use in the week prior to randomization for one of substances (cocaine, heroin, cannabis or alcohol) assessed by the TLFB interview. 4. Stable dose of antipsychotic agent for at least one month.
RESEARCH. INNOVATION. DISCOVERY.